

DAFTAR PUSTAKA

1. Dara, A. I., & Husni, P. Artikel Tinjauan: Teknik Meningkatkan Kelarutan Obat. 2017; 15(4);49-57. <https://doi.org/10.24198/jf.v15i4.14684.g7468>
2. Sari, D. P., Sulaiman, T. S., & Mafruhah, O. R. Uji Disolusi Terbanding Tablet Metformin Hidroklorida Generik Bermerk. Majalah Farmasetik. 2013; 9(1); 254-258. <https://doi.org/10.22146/farmasetik.v9i1.24106>
3. Jannin, V., Musakhanian, J., & Marchaud, D. *Approaches for the development of solid and semi-solid lipid-based formulations*. ScienceDirect. 2008; 60(6); 734-746. <http://dx.doi.org/10.1016/j.addr.2007.09.006>
4. Mokale, V., Naik, S., Khatal, T., Sonawane, S. H., & Potoroko, I. *Formulation development and in vitro multimedia drug release study of solid self-microemulsifying drug delivery system of ketoconazole for enhanced solubility and pH-independent dissolution profile*. In book: Encapsulation of Active Molecules and Their Delivery System. 2020; 211-231. <https://doi.org/10.1016/B978-0-12-819363-1.00013-2>
5. Hussain, A., Ali, I., Khan, A. U., & Khan, T. M. *Glibenclamide-induced profound hypoglycaemic crisis: a case report*. University College London. 2016; 7(2); 84-87. <https://doi.org/10.1177/2042018816632440>

6. Zhang, G., Lin, X., Zhang, S., Xiu, H., Pan, C., & Cui, W. *A Protective Role of Glibenclamide in Inflammation Associated Injury*. Hindawi, 2017; 2017; 1-12. <https://doi.org/10.1155/2017/3578702>

7. MIMS Glibenclamide. (2020). MIMS.
<https://www.mims.com/indonesia/drug/info/glibenclamide?mtype=generic>

8. Budiman, A., Megantara, S., Sholihah, R., & Amin, S. *Synthesis of Glibenclamide-Oxalic Acid Cocystal using Thermal Solvent-Free Method*. International Journal of Pharmaceutical Quality Assurance, 2020;11(2); 404-408. <http://dx.doi.org/10.25258/ijpqa.11.3.16>

9. Liang, Y., Arakawa, K., Ueta, K., Matrushita, Y., Kuriyama, C., Martin, T., et al. *Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models*. University of Padova Medical School, 2012; 7(2); 1-7.
<https://doi.org/10.1371%2Fjournal.pone.0030555>

10. Sha, S., Devineni, D., Ghosh, A., Polidori, D., Hompesch, M., Arnolds, S., et al. *Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes*. University of Tolima, 2014; 9(8); 1-12.
<https://doi.org/10.1371/journal.pone.0105638>

11. Inagaki, N., Kondo, K., Yoshinari, T., Ishii, M., Sakai, M., Kuki, H., et al.
Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment. Clin Drug Investig, 2014; 34(10); 731-742.
<https://doi.org/10.1007%2Fs40261-014-0226-x>
12. Yale, J F; Bakris, G; Cariou, B; Yue, D; Neto, E David; Xi, L; Figueroa, K; Wajs, E; Usiskin, K; Meininger, G. *Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.* Diabetes, Obesity and Metabolism, 2013;15(5); 463-473.
<http://dx.doi.org/10.1111/dom.12090>
13. Eliskon, S., & Scott, L. J. (2013). *Canagliflozin: First Global Approval.* Drugs, 2013; 73(16); 979-988. <http://dx.doi.org/10.1007/s40265-013-0064-9>
14. MIMS Canagliflozin. (2022). MIMS.
<https://www.mims.com/indonesia/drug/info/canagliflozin?mtype=generic>
15. Dormandy, J. A., Charbonnel, B., Ecklan, D. J., Erdmann, E., Bennedetti, M. M., Moules, I. K., et al. *Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.* Lancet, 2005; 366(9493); 1279-1289.
[http://dx.doi.org/10.1016/S0140-6736\(05\)67528-9](http://dx.doi.org/10.1016/S0140-6736(05)67528-9)

16. Jarvinen, H. Y. *Drug Therapy Thiazolidinediones*. The new england journal of medicine, 2004; 351(11); 1106-1118.
<http://dx.doi.org/10.1056/NEJMra041001>

17. DeFronzo, R. A., Inzucchi, S., Ghani, A. M., & Nissen, E. S. *Pioglitazone: The forgotten, cost-effective Pioglitazone: The forgotten, cost-effective*. Diabetes & Vascular Disease Research, 2019; 16(2): 133-143.
<http://dx.doi.org/10.1177/1479164118825376>

18. Alam, F., Islam, M. A., Mohamed, M., Ahmad, I., Kamal, M. A., Donnelly, R., et al. *Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials*. Scientific Reports, 2019; 9(1); 5389.
<https://www.nature.com/articles/s41598-019-41854-2>

19. MIMS Pioglitazone. (2022). MIMS.
<https://www.mims.com/indonesia/drug/info/pioglitazone?mtype=generic>

20. Gandini, A. L., Pranggono, E., & Ropi, H. Pengaruh Pendidikan Kesehatan Terhadap Pengetahuan, Perilaku Dan Gula Darah Pada Pasien Diabetes Mellitus Tipe 2. Jurnal Husada Mahakam, 2015; 3(9); 452-522.
<http://issn.pdii.lipi.go.id/issn.cgi?daftar&&&&1978-8355>

21. Decroli, E. Diabetes Melitus Tipe 2 (1 ed., Vol. I). Padang, Indonesian: Pusat Penerbitan Bagian Ilmu Penyakit Dalam. 2019. 1-48p.

22. Chan, J. L., & Abrahamson, M. J. *Pharmacological Management of Type 2 Diabetes Mellitus: Rationale for Rational Use of Insulin*. Mayo Clin Proc, 2003; 78(4); 459-467. <https://doi.org/10.4065/78.4.459>
23. Collaboration, T. E. *Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies*. Lancet, 2010; 375(9733); 2215-2222. [https://doi.org/10.1016/S0140-6736\(10\)60484-9](https://doi.org/10.1016/S0140-6736(10)60484-9)
24. Dokken, B. *The Kidney as a Treatment Target for Type 2 Diabetes*. Diabetes Spectrum. 2012; 25(1); 29-36. <https://doi.org/10.2337/diaspect.25.1.29>
25. Matheus, A. S., Tannus, L. R., Cobas, R. A., Palma, C. C., Negrato, C. A., & Gomes, M. d. *Impact of Diabetes on Cardiovascular Disease: An Update*. Hindawi, 2013; 2013(653789); 1-16. <https://doi.org/10.1155/2013/653789>
26. Bulugahapitiya, U., Siyambalapitiya, S., Sithole, J., & Idris, I. *Original Article: Epidemiology Is diabetes a coronary risk equivalent? Systematic review and meta-analysis*. Diabetic Medicine, 2009; 26(2); 142-148. <http://dx.doi.org/10.1111/j.1464-5491.2008.02640.x>
27. Nanayakkara, N., Curtis, A. J., Heritier, S., Gadowski, A. M., Parkov, M. E., Kenealy, T., et al. *Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-*


analyses. *Diabetologia*, 2021; 64; 275-287. <https://doi.org/10.1007/s00125-020-05319-w>

28. Lathifah, N. L. Hubungan Durasi Penyakit Dan Kadar Gula Darah Dengan Keluhan Subyektif Penderita Diabetes Melitus. *Jurnal Berkala Epidemiologi*, 2017; 5(2); 231-239.
<http://dx.doi.org/10.20473/jbe.V5I22017.218-230>
29. Siregar, C. J. *Teknologi Farmasi Sediaan Tablet Dasar-Dasar Praktis*. Jakarta: Buku Kedokteran. 2010. 55-121p.
30. Hisprastin, Y., & Nuwarda, R. F. Review: Perbedaan Emulsi Dan Mikroemulsi Pada Minyak Nabati. *Farmaka*. 2018; 16(1); 133-140.
<https://doi.org/10.24198/jf.v16i1.17424>
31. Gozali, D., Waheda, F., Levita, J., & Khoirunisa, A. Peningkatan Permeasi Mikroemulsi Ketoprofen. *IJPST*, 2015; 2(2); 55-62.
<https://doi.org/10.15416/ijpst.v2i2.7811>
32. Jufri, M., Djajadisastra, J., & Maya, L. Pembuatan Mikroemulsi Dari Minyak Buah Merah. *Majalah Ilmu Kefarmasian*, 2009; 6(1); 18-27.
<http://dx.doi.org/10.7454/psr.v6i1.3432>
33. Gosh, P. K., & Murthy, R. S. *Microemulsions: A Potential Drug Delivery System*. *Current Drug Delivery*, 2006; 3(2); 167-180.
<http://dx.doi.org/10.2174/156720106776359168>

34. Hanh, N. D., Mitrevej, A., Sathirakul, K., Peungvicha, P., & Sinchaipanid, N. *Development of phyllanthin-loaded self-microemulsifying drug delivery system for oral bioavailability enhancement*. *Drug Dev Ind Pharm*. 2013; 41(2); 207-217. <https://doi.org/10.3109/03639045.2013.858732>
35. Kanoujia, K., Dewangan, C., Masih, A., Sinha, D., Oraon, D., Jaiswal, M., et al. *Self Microemulsifying Drug Delivery System (SMEDDS): A New Approach to Improve The Therapeutic Efficacy of Orally Administered Drugs*. *Research Journal of Pharmaceutical Dosage Forms and Technology*. 2018; 10(2), 95-102. <http://dx.doi.org/10.5958/0975-4377.2018.00015.0>
36. Akula, S., Gurram, A. K., & Devireddy, S. R. *Self-Microemulsifying Drug Delivery Systems: An Attractive Strategy for Enhanced Therapeutic Profile*. *Hindiaaw.*,2014; 2014(964051); 1-11. <https://doi.org/10.1155/2014/964051>
37. Dokania, S., & Joshi, A. K. *Self-microemulsifying drug delivery system (SMEDDS) – challenges and road ahead*. *Drug Deliver*. 2015; 22(6); 675-690. <https://doi.org/10.3109/10717544.2014.896058>
38. Swastika, I. N., Ristiani, N. K., Gorintha, A. W., & Indrayani, A. W. *Potensi Formulasi Self Microemulsifying Drug Delivery System (SMEDDS) Ekstrak Biji Kedelai (Glycine soja) Terhadap Penurunan Kolesterol pada Penyakit Jantung Koroner*. *Jurnal Epidemiologi Kesehatan Komunitas*. 2021; 6(2); 247-253. <https://doi.org/10.14710/jekk.v6i2.12190>


39. Artanti, A. N., Prihapsara, F., Ermawati, D. E., & Shofa, A. S. *Optimization of Self-Micro Emulsifying Drug Delivery System) for Soursop Leaf (Annona muricata Linn.) Chloroform Extract*. Trad. Med. J. 2020; 25(2); 81-87. <http://dx.doi.org/10.22146/mot.51590>
40. Wahyuningsih, I., Sugiyanto, Yuswanto, A., & Martien, R. Uji Kelarutan Untuk Seleksi Fase Minyak, Surfaktan Dan Kosurfaktan Dalam Preparasi *Self-Nano Emulsifying Drug Delivery System (SNEDDS)* Furosemid. *Prosiding Seminar Nasional Peluang Herbal Sebagai Alternatif Medicine*, 2015; 99-104. <http://dx.doi.org/10.31942/jiffk.v0i0.1351>
41. Bachhav, Y. G., & Patravale, V. B. *SMEDDS of Glyburide: Formulation, In Vitro Evaluation, and Stability Studies*. AAPS PharmSciTech, 2009; 10(2); 482-487. <https://doi.org/10.1208%2Fs12249-009-9234-1>
42. Pandey, V., & Kohli, S. *SMEDDS of pioglitazone: Formulation, in-vitro evaluation and stability studies*. Future Journal of Pharmaceutical sciences. 2017; 3(1); 53-59. <http://dx.doi.org/10.1016/j.fjps.2017.02.003> Singh, D., Tiwary, A. K., & Bedi, N. *Canagliflozin loaded SMEDDS: formulation optimization for improved solubility, permeability and pharmacokinetic performance*. Journal of Pharmaceutical Investigation. 2018; 49(2); 67-85. <http://dx.doi.org/10.1007/s40005-018-0385-5>

LAMPIRAN 1
BUKTI SUBMIT ARTIKEL



Gambar I.1 Bukti submit artikel

LAMPIRAN 2

ALUR PEMBUATAN *REVIEW* ARTIKELGambar II.1 Alur pembuatan *review* artikel